Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 2025 financial results and updates on belapectin trial data
Galectin Therapeutics Inc. reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, for the quarter ended September 30, 2025, compared to a net loss of $11.2 million, or ($0.18) per share, for the same period in 2024. Research and development expenses were $2.6 million, down from $7.6 million in the prior year, primarily due to the conclusion of expenditures related to the NAVIGATE clinical trial. General and administrative expenses were $1.6 million, compared to $1.5 million in the previous year. As of September 30, 2025, the company held $11.5 million in cash and cash equivalents and entered into a $10 million line of credit in July 2025. The company submitted the NAVIGATE data package to the FDA and expects guidance by year-end, with sufficient cash to fund current plans through June 30, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-042118), on November 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。